BCM
AXSM icon

BlueCrest Capital Management’s Axsome Therapeutics AXSM Stock Holding History

BlueCrest Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-4,227
Closed -$437K – 235
2019
Q4 		$437K Buy
+4,227
New +$171K 0.03% 220

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlueCrest Capital Management's AXSM Position: Q1 2020 in Review

BlueCrest Capital Management sold out of Axsome Therapeutics (AXSM) in Q1 2020, closing a stake of 4,227 shares — an estimated $437K sold.

BlueCrest Capital Management first reported a position in AXSM in Q4 2019 and held it in 1 quarter. The position peaked at $437K in Q4 2019. 163 funds tracked by Wall St. Rank hold AXSM as of Q1 2020.

  • BlueCrest Capital Management reported no remaining Axsome Therapeutics position as of Q1 2020 after selling out during the quarter.
  • BlueCrest Capital Management sold 4,227 Axsome Therapeutics shares in Q1 2020, an estimated $437K.
  • BlueCrest Capital Management first reported a position in Axsome Therapeutics in Q4 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Axsome Therapeutics position peaked at $437K in Q4 2019.
  • 163 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2020.

Based on BlueCrest Capital Management's 13F filing for Q1 2020, filed 15 May 2020.